Possible changes in the standard of care for prostate cancer
New Perspectives in the Management of Prostate Cancer | ESMO
PDF) Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Women for Mankind: Optimal Use of Chemotherapy in Metastatic Prostate Cancer | ESMO
Mapping Pathways for PARP Inhibition in Prostate Cancer: Practical Considerations for Clinical Practice | ESMO
ESMO Preceptorship on Prostate Cancer 2022: Lugano
Fred Saad, ESMO 2022: Phase 3 PROpel trial of abiraterone and olaparib for patients with prostate cancer - Biomarker analysis and updated results - touchONCOLOGY
Table 2 from Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. | Semantic Scholar
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† - Annals of Oncology
Is Earlier Better? Translating Clinical Evidence into Individualised Treatment Decisions in Advanced Prostate Cancer | ESMO
Possible changes in the standard of care for prostate cancer
Women Against Prostate Cancer: Optimal Use of Chemotherapy in Metastatic Prostate Cancer | ESMO
Prostate Cancer Highlights from ESMO 2022 - YouTube
ESMO 2022: Metastatic Castration-Sensitive Prostate Cancer 2022 Updates Discussion
Prostate Cancer Highlights from ESMO 2022 - YouTube
ESMO 2021: A Phase 3 Trial With a 2x2 Factorial Design in Men With De Novo Metastatic Castration-Sensitive Prostate Cancer: Overall Survival With Abiraterone Acetate Plus Prednisone in PEACE-1
ESMO Guidelines: Real World Cases - Webinar Series: March 2021
ESMO 2019: Overall Survival Interim Analysis Results of the Phase 3 SPARTAN Trial
Olaparib Outperforms Enzalutamide or Abiraterone Acetate
ESMO Virtual Advanced Course on Clinical Questions in Prostate
Elucidate Metastatic Prostate Cancer Targets with Radioligand Therapy and Molecular Profiling: Advancing Precision Medicine in Prostate Cancer | ESMO
ESMO Virtual Preceptorship on Prostate Cancer 2020
Application of Liquid Biopsy Webinar Series – Prostate Cancer
Sequencing Life-Prolonging Agents in Prostate Cancer | ESMO
Guidelines for genetic testing
